Skip to main content
LIFECORE BIOMEDICAL, INC. \DE\ logo

LIFECORE BIOMEDICAL, INC. \DE\ — Investor Relations & Filings

Ticker · LFCR ISIN · US5147661046 LEI · 549300EHBZ5OM9ND9O43 US Manufacturing
Open in API
Filings indexed 1,096 across all filing types
Latest filing 2010-07-09 Regulatory Filings
Country US United States of America
Listing US LFCR

About LIFECORE BIOMEDICAL, INC. \DE\

https://www.lifecore.com/

Lifecore Biomedical is an integrated contract development and manufacturing organization (CDMO) that specializes in sterile injectable pharmaceutical drug products and medical devices. The company provides a full range of services, including specialty formulation, process development, aseptic filling, and final packaging, supporting products from clinical phases through to commercial supply. A key area of expertise is the handling of complex and highly viscous formulations. In addition to its CDMO capabilities, Lifecore is a primary producer of non-animal-sourced sodium hyaluronate (hyaluronic acid), offering it in various molecular weights and formats, including bulk material, hydrogels, and filled syringes and vials for diverse applications.

Recent filings

Filing Released Lang Actions
8-K/A Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K/A filed with the SEC, which is an amendment to a previously filed Form 8-K. It includes financial statements of a business acquired (Lifecore Biomedical, Inc.) and pro forma financial information related to the acquisition. The presence of audited financial statements and pro forma financials indicates substantive financial data related to a significant transaction. The document is not a full annual report but rather a current report amendment focusing on acquisition-related financial disclosures. This fits the category of a Regulatory Filing (RNS) because Form 8-K and its amendments are current reports filed to disclose material events, including acquisitions, and are not annual or quarterly reports themselves. The document length is 3307 characters, which is relatively short and consistent with a regulatory filing rather than a full report. Therefore, the best classification is Regulatory Filings (RNS).
2010-07-09 English
8-K Filing
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on changes in executive compensation, including bonuses, stock option grants, restricted stock units, and salary increases for named executive officers. There is no financial statement or comprehensive financial data presented, nor is it an earnings release or annual report. The key content is about changes in management compensation and appointments, which aligns with announcements related to board or management information. Therefore, the document fits best under the category for Board/Management Information (MANG). The document length is 4486 characters, which is consistent with a detailed announcement rather than a brief notice or a full report.
2010-06-01 English
4 Filing
Director's Dealing
2010-05-28 English
4 Filing
Director's Dealing
2010-05-28 English
4 Filing
Director's Dealing
2010-05-28 English
4 Filing
Director's Dealing
2010-05-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.